A fresh licensing deal tidies up years of work between the two companies.

Furvent, in first-line EGFR exon 20 insertion lung cancer, reads out imminently.

Silevertinib trial will evaluate patients with unmethylated MGMT and EGFRvIII mutations. 

JNJ-95566692 enters phase 1, with Qilu neck and neck.

Majestec-9, in post-Darzalex multiple myeloma, is the latest success.

But PFS data are lacking, and there are questions about first and second-line plans.